Adaptimmune (NASDAQ:ADAP) inks an agreement with Tokyo-based Noile-Immune Biotech to co-develop next-generation SPEAR T-cell products incorporating the latter’s PRIME (proliferation-inducing and migration-enhancing) technology to augment CAR-T cell activity.
Under the terms of the agreement, ADAP will pay Noile-Immune up to $312M across all programs plus mid-single-digit royalties on net sales. ADAP will have exclusive rights to develop and commercialize all products on a global basis.
Shares are up 3% premarket on light volume.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.